View Item 

Show simple item record

Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC
dc.contributor.authorBayes-Genis, Antoni
dc.contributor.authorDocherty, Kieran F.
dc.contributor.authorPetrie, Mark C.
dc.contributor.authorJanuzzi, James L.
dc.contributor.authorMueller, Christian
dc.contributor.authorAnderson, Lisa
dc.contributor.authorBozkurt, Biykem
dc.contributor.authorButler, Javed
dc.contributor.authorChioncel, Ovidiu
dc.contributor.authorCleland, John G.F.
dc.contributor.authorChristodorescu, Ruxandra
dc.contributor.authorDel Prato, Stefano
dc.contributor.authorGustafsson, Finn
dc.contributor.authorLam, Carolyn S.P.
dc.contributor.authorMoura, Brenda
dc.contributor.authorPop-Busui, Rodica
dc.contributor.authorSeferovic, Petar
dc.contributor.authorVolterrani, Maurizio
dc.contributor.authorVaduganathan, Muthiah
dc.contributor.authorMetra, Marco
dc.contributor.authorRosano, Giuseppe
dc.date.accessioned2024-01-04T21:58:26Z
dc.date.available2024-12-04 16:58:24en
dc.date.available2024-01-04T21:58:26Z
dc.date.issued2023-11
dc.identifier.citationBayes-Genis, Antoni ; Docherty, Kieran F.; Petrie, Mark C.; Januzzi, James L.; Mueller, Christian; Anderson, Lisa; Bozkurt, Biykem; Butler, Javed; Chioncel, Ovidiu; Cleland, John G.F.; Christodorescu, Ruxandra; Del Prato, Stefano; Gustafsson, Finn; Lam, Carolyn S.P.; Moura, Brenda; Pop-Busui, Rodica ; Seferovic, Petar; Volterrani, Maurizio; Vaduganathan, Muthiah; Metra, Marco; Rosano, Giuseppe (2023). "Practical algorithms for early diagnosis of heart failure and heart stress using NT- proBNP: A clinical consensus statement from the Heart Failure Association of the ESC." European Journal of Heart Failure 25(11): 1891-1898.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/191833
dc.description.abstractDiagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. This document from the Heart Failure Association examines the practical uses of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in various clinical scenarios. The concentrations of NT-proBNP vary according to the patient profile and the clinical scenario, therefore values should be interpreted with caution to ensure appropriate diagnosis. Validated cut-points are provided to rule in or rule out acute heart failure in the emergency department and to diagnose de novo heart failure in the outpatient setting. We also coin the concept of ‘heart stress’ when NT-proBNP levels are elevated in an asymptomatic patient with risk factors for heart failure (i.e. diabetes, hypertension, coronary artery disease), underlying the development of cardiac dysfunction and further increased risk. We propose a simple acronym for healthcare professionals and patients, FIND-HF, which serves as a prompt to consider heart failure: Fatigue, Increased water accumulation, Natriuretic peptide testing, and Dyspnoea. Use of this acronym would enable the early diagnosis of heart failure. Overall, understanding and utilizing NT-proBNP levels will lead to earlier and more accurate diagnoses of heart failure ultimately improving patient outcomes and reducing healthcare costs.
dc.publisherJohn Wiley & Sons, Ltd.
dc.subject.otherNatriuretic peptides
dc.subject.otherNT-proBNP
dc.subject.otherHeart failure
dc.titlePractical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191833/1/ejhf3036.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191833/2/ejhf3036_am.pdf
dc.identifier.doi10.1002/ejhf.3036
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceLee KK, Doudesis D, Anwar M, Astengo F, Chenevier-Gobeaux C, Claessens YE, et al. CoDE-HF investigators. Development and validation of a decision support tool for the diagnosis of acute heart failure: Systematic review, meta-analysis, and modelling study. BMJ 2022; 377: e068424. https://doi.org/10.1136/bmj-2021-068424
dc.identifier.citedreferenceMyhre PL, Prescott MF, Claggett B, Felker GM, Butler J, Piña IL, et al. Comparative effect of angiotensin receptor neprilysin inhibition on B-type natriuretic peptide levels measured by three different assays: The PROVE-HF study. Clin Chem 2022; 68: 1391 – 1398. https://doi.org/10.1093/clinchem/hvac148
dc.identifier.citedreferenceSeferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. The Heart Failure Association Atlas: Heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021; 23: 906 – 914. https://doi.org/10.1002/ejhf.2143
dc.identifier.citedreferenceMueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21: 715 – 731. https://doi.org/10.1002/ejhf.1494
dc.identifier.citedreferenceBottle A, Kim D, Aylin P, Cowie MR, Majeed A, Hayhoe B. Routes to diagnosis of heart failure: Observational study using linked data in England. Heart 2018; 104: 600 – 605. https://doi.org/10.1136/heartjnl-2017-312183
dc.identifier.citedreferenceGreen SM, Martinez-Rumayor A, Gregory SA, Baggish AL, O’Donoghue ML, Green JA, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008; 168: 741 – 748. https://doi.org/10.1001/archinte.168.7.741
dc.identifier.citedreferenceDao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379 – 385. https://doi.org/10.1016/s0735-1097(00)01156-6
dc.identifier.citedreferenceCollins SP, Lindsell CJ, Storrow AB, Abraham WT; ADHERE Scientific Advisory Committee, Investigators and Study Group. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006; 47: 13 – 18. https://doi.org/10.1016/j.annemergmed.2005.04.003
dc.identifier.citedreferenceBayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6: 301 – 308. https://doi.org/10.1016/j.ejheart.2003.12.013
dc.identifier.citedreferenceLam LL, Cameron PA, Schneider HG, Abramson MJ, Müller C, Krum H. Meta-analysis: Effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010; 153: 728 – 735. https://doi.org/10.7326/0003-4819-153-11-201012070-00006
dc.identifier.citedreferenceMoe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients with Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 3103 – 3110. https://doi.org/10.1161/CIRCULATIONAHA.106.666255
dc.identifier.citedreferenceKozhuharov N, Sabti Z, Wussler D, Nowak A, Badertscher P, Twerenbold R, et al.; BASEL V Investigators. Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. Eur J Heart Fail 2019; 21: 813 – 815. https://doi.org/10.1002/ejhf.1471
dc.identifier.citedreferenceMueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647 – 654. https://doi.org/10.1056/NEJMoa031681
dc.identifier.citedreferenceSiebert U, Milev S, Zou D, Litkiewicz M, Gaggin HK, Tirapelle L, et al. Economic evaluation of an N-terminal pro B-type natriuretic peptide-supported diagnostic strategy among dyspneic patients suspected of acute heart failure in the emergency department. Am J Cardiol 2021; 147: 61 – 69. https://doi.org/10.1016/j.amjcard.2021.01.036
dc.identifier.citedreferenceMueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006; 166: 1081 – 1087. https://doi.org/10.1001/archinte.166.10.1081
dc.identifier.citedreferenceJanuzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP study. Eur Heart J 2006; 27: 330 – 337. https://doi.org/10.1093/eurheartj/ehi631
dc.identifier.citedreferenceJanuzzi JL Jr, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy PD, et al.; ICON-RELOADED Investigators. N-terminal pro-B-type natriuretic peptide in the emergency department: The ICON-RELOADED study. J Am Coll Cardiol 2018; 71: 1191 – 1200. https://doi.org/10.1016/j.jacc.2018.01.021
dc.identifier.citedreferenceBayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordoñez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167: 400 – 407. https://doi.org/10.1001/archinte.167.4.400
dc.identifier.citedreferencevan Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, et al. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: Redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621 – 1627. https://doi.org/10.1016/j.jacc.2006.06.056
dc.identifier.citedreferencede Filippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53: 1511 – 1519. https://doi.org/10.1373/clinchem.2006.084533
dc.identifier.citedreferenceO’Donoghue M, Kenney P, Oestreicher E, Anwaruddin S, Baggish AL, Krauser DG, et al. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE study). Am J Cardiol 2007; 100: 1336 – 1340. https://doi.org/10.1016/j.amjcard.2007.06.020
dc.identifier.citedreferencevan Kimmenade RR, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol 2008; 101: 39 – 42. https://doi.org/10.1016/j.amjcard.2007.11.018
dc.identifier.citedreferenceSalah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: A European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF score. Heart 2014; 100: 115 – 125. https://doi.org/10.1136/heartjnl-2013-303632
dc.identifier.citedreferenceSchou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007; 28: 177 – 182. https://doi.org/10.1093/eurheartj/ehl449
dc.identifier.citedreferenceJanuzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013; 127: 500 – 508. https://doi.org/10.1161/CIRCULATIONAHA.112.120485
dc.identifier.citedreferenceRoalfe AK, Lay-Flurrie SL, Ordóñez-Mena JM, Goyder CR, Jones NR, Hobbs FDR, et al. Long term trends in natriuretic peptide testing for heart failure in UK primary care: A cohort study. Eur Heart J 2021; 43: 881 – 891. https://doi.org/10.1093/eurheartj/ehab781
dc.identifier.citedreferenceNational Institute for Health and Care Excellence. Heart failure guidance. www.nice.org.uk/Guidance/Conditions-and-diseases/Cardiovascular-conditions/Heart-failure. Accessed 17 September 2023.
dc.identifier.citedreferenceWelsh P, Campbell RT, Mooney L, Kimenai DM, Hayward C, Campbell A, et al. Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circ Heart Fail 2022; 15: e009427. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009427
dc.identifier.citedreferenceMu S, Echouffo-Tcheugui JB, Ndumele CE, Coresh J, Juraschek S, Brady T, et al. NT-proBNP reference intervals in healthy U.S. children, adolescents, and adults. J Appl Lab Med 2023; 8: 700 – 712. https://doi.org/10.1093/jalm/jfad024
dc.identifier.citedreferenceMyhre PL, Claggett B, Yu B, Skali H, Solomon SD, Røsjø H, et al. Sex and race differences in N-terminal pro-B-type natriuretic peptide concentration and absolute risk of heart failure in the community. JAMA Cardiol 2022; 7: 623 – 631. https://doi.org/10.1001/jamacardio.2022.0680
dc.identifier.citedreferenceKeyzer JM, Hoffmann JJ, Ringoir L, Nabbe KC, Widdershoven JW, Pop VJ. Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care. Clin Chem Lab Med 2014; 52: 1341 – 1346. https://doi.org/10.1515/cclm-2013-0791
dc.identifier.citedreferenceHildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010; 31: 1881 – 1889. https://doi.org/10.1093/eurheartj/ehq163
dc.identifier.citedreferenceCleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, et al. The struggle towards a universal definition of heart failure – how to proceed? Eur Heart J 2021; 42: 2331 – 2343. https://doi.org/10.1093/eurheartj/ehab082
dc.identifier.citedreferenceTaylor CJ, Lay-Flurrie SL, Ordóñez-Mena JM, Goyder CR, Jones NR, Roalfe AK, et al. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-2018. Heart 2022; 108: 543 – 549. https://doi.org/10.1136/heartjnl-2021-319196
dc.identifier.citedreferenceNatriuretic Peptides Studies Collaboration; Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, et al., Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. Lancet Diabetes Endocrinol 2016 4 ( 10 ): 840 – 849. https://doi.org/10.1016/S2213-8587(16)30196-6
dc.identifier.citedreferenceScirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. SAVOR-TIMI 53 Steering Committee and Investigators*. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579 – 1588. https://doi.org/10.1161/CIRCULATIONAHA.114.010389
dc.identifier.citedreferenceMagnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004; 27: 1929 – 1935. https://doi.org/10.2337/diacare.27.8.1929
dc.identifier.citedreferenceVerma S, Sharma A, Kanumilli N, Butler J. Predictors of heart failure development in type 2 diabetes: A practical approach. Curr Opin Cardiol 2019; 34: 578 – 583. https://doi.org/10.1097/HCO.0000000000000647
dc.identifier.citedreferenceBayes-Genis A, Coats AJS. ’Peptide for Life’ in primary care: Work in progress. Eur Heart J 2022; 43: 892 – 894. https://doi.org/10.1093/eurheartj/ehab829
dc.identifier.citedreferenceMcDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4 – 131. https://doi.org/10.1002/ejhf.2333
dc.identifier.citedreferenceGuidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995; 16: 741 – 751.
dc.identifier.citedreferenceHeidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79: 1757 – 1780. https://doi.org/10.1016/j.jacc.2021.12.011
dc.identifier.citedreferenceRevuelta-López E, Barallat J, Cserkóová A, Gálvez-Montón C, Jaffe AS, Januzzi JL, et al. Pre-analytical considerations in biomarker research: Focus on cardiovascular disease. Clin Chem Lab Med. 2021; 59: 1747 – 1760.
dc.identifier.citedreferencePop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: An underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care 2022; 45: 1670 – 1690. https://doi.org/10.2337/dci22-0014
dc.identifier.citedreferenceBozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23: 352 – 380. https://doi.org/10.1002/ejhf.2115
dc.identifier.citedreferenceChioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574 – 1585. https://doi.org/10.1002/ejhf.813
dc.identifier.citedreferenceMukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402 – 1412. https://doi.org/10.1172/JCI115146
dc.identifier.citedreferencePemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36: 355 – 359. https://doi.org/10.1161/01.hyp.36.3.355
dc.identifier.citedreferenceMeijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: Review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail 2021; 23: 1610 – 1632. https://doi.org/10.1002/ejhf.2346
dc.identifier.citedreferenceAzzazy HM, Christenson RH, Duh SH. Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems. Clin Chim Acta 2007; 384: 176 – 178. https://doi.org/10.1016/j.cca.2007.05.025
dc.identifier.citedreferenceMyhre PL, Prescott MF, Murphy SP, Fang JC, Mitchell GF, Ward JH, et al. Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: A pooled analysis of EVALUATE-HF and PROVE-HF. JACC Heart Fail 2022; 10: 119 – 128. https://doi.org/10.1016/j.jchf.2021.09.007
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf3036.pdf
Size:
625.2KB
Format:
PDF
View/Open
Name:
ejhf3036_am.pdf
Size:
2.220MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.